Psilocybin-Assisted Therapy Receives FDA Priority Review for Treatment-Resistant Depression

How Does Psilocybin Therapy Work for Depression?

Psilocybin, the active compound in psychedelic mushrooms, is converted in the body to psilocin, which acts primarily as an agonist at serotonin 5-HT2A receptors. Unlike daily antidepressants that modulate serotonin levels chronically, psilocybin produces a brief but intense period of heightened brain connectivity and neural plasticity lasting 4-6 hours — what neuroscientists describe as a 'window of plasticity.'

Neuroimaging studies, including work by Robin Carhart-Harris and colleagues at Imperial College London, show that psilocybin temporarily disrupts the default mode network (DMN), a brain network associated with self-referential thinking, rumination, and the rigid negative thought loops characteristic of depression. During this disruption, new neural connections form between brain regions that don't normally communicate, facilitating cognitive flexibility and new perspectives. Combined with professional psychological support before, during, and after the session, patients often report breakthrough insights and emotional processing that produce lasting mood improvement.

What Did the Clinical Trials Show?

The pivotal Phase 2b trial, published in the New England Journal of Medicine in 2022 by Goodwin et al., enrolled 233 adults with treatment-resistant depression who had failed at least 2 adequate antidepressant trials. Participants were randomized to receive a single dose of 25mg, 10mg, or 1mg (active control) psilocybin in a supervised clinical setting with trained therapist support, preceded by preparation sessions and followed by integration therapy.

The results showed that the 25mg group had a significantly greater reduction in MADRS depression scores at 3 weeks compared to the 1mg control group. Approximately 29% of patients in the 25mg group achieved remission (MADRS ≤10) compared to about 8% in the control group. Response rates (≥50% symptom reduction) were also significantly higher in the 25mg group. A separate open-label study by Carhart-Harris and colleagues found that antidepressant effects from psilocybin could persist for several months in some patients. COMPASS Pathways has since advanced to Phase 3 trials to confirm these findings in larger, more diverse patient populations, with results anticipated in the coming years.

How Is Psilocybin Therapy Administered?

Psilocybin therapy is not a 'take a pill and go home' treatment — it is a structured therapeutic intervention requiring certified professionals and specialized settings. The COMP360 protocol consists of three phases:

Preparation (typically 2-3 sessions): Therapists assess readiness, establish therapeutic rapport, set intentions, and prepare the patient for the psychedelic experience. Patients are screened for contraindications including psychotic spectrum disorders, bipolar I disorder, and certain cardiovascular conditions. Dosing session (1 day): The patient takes a single 25mg psilocybin capsule in a comfortable, supervised room and spends approximately 6-8 hours with continuous therapist presence. Vital signs are monitored throughout. Integration (typically 2-3 sessions): In the days and weeks following, therapists help patients process insights, develop new coping strategies, and consolidate therapeutic gains from the experience.

What Are the Risks and Side Effects?

The psychedelic experience itself can be psychologically challenging. In the Phase 2b trial, the most common adverse events in the 25mg group included headache, nausea, fatigue, and emotional distress. Transient anxiety during the session was also frequently reported. These effects generally resolved within the dosing session or within a few days and were managed with therapist support. Transient increases in blood pressure and heart rate during the experience were observed, consistent with psilocybin's known pharmacological profile.

Serious adverse events were reported more frequently in the 25mg group than the control group, including cases of suicidal ideation and self-harm behavior — a finding that highlighted the need for careful patient selection and monitoring. The Phase 2b investigators noted that treatment-resistant depression itself carries high baseline risk for suicidality, making it difficult to disentangle drug effects from underlying illness. The structured therapeutic setting with trained professionals appears to substantially reduce the risks associated with unsupervised psychedelic use, and Phase 3 trials include enhanced safety monitoring protocols.